WO WO2006078942A2
· 2006
[cited by examiner]
International Preliminary Report on Patentability mailed Jan. 25, 2022, issued in corresponding International Application No. PCT/US2020/043203, filed Jul. 23, 2020, 6 pages.
[cited by applicant]
Armstrong, Andrew J., et al. “A pharmacodynamic study of rapamycin in men with intermediate-to high-risk localized prostate cancer.” Clinical cancer research 16.11 (2010). 17 pages.
[cited by applicant]
Beltran, Himisha, et al. “Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.” Nature medicine 22.3 (2016). 24 pages.
[cited by applicant]
Bianchini, Andrea, et al. “Phosphorylation of elF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.” Carcinogenesis 29.12 (2008): 2279-2288.
[cited by applicant]
Bluemn, Eric G., et al. “Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling.” Cancer cell 32.4 (2017): 474-489, e1-e6.
[cited by applicant]
Cencic, Regina, et al. “Blocking elF4E-elF4G interaction as a strategy to impair coronavirus replication.” Journal of virology 85.13 (2011): 6381-6389.
[cited by applicant]
Cencic, Regina, et al. “Reversing chemoresistance by small molecule inhibition of the translation initiation complex elF4F.” Proceedings of the National Academy of Sciences 108.3 (2011): 1046-1051.
[cited by applicant]
De Bono, Johann S., et al. “Abiraterone and increased survival in metastatic prostate cancer.” New England Journal of Medicine 364.21 (2011): 1995-2005.
[cited by applicant]
Dehm, Scott M., and Donald J. Tindall. “Androgen receptor structural and functional elements: role and regulation in prostate cancer.” Molecular endocrinology 21.12 (2007): 2855-2863.
[cited by applicant]
Dowling, Ryan Jo, et al. “mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs.” Science 328.5982 (2010). 9 pages.
[cited by applicant]
Dubois, Vanessa, et al. “Androgen deficiency exacerbates high-fat diet-induced metabolic alterations in male mice.” Endocrinology 157.2 (2016): 648-665.
[cited by applicant]
Furic, Luc, et al. “elF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.” Proceedings of the National Academy of Sciences 107.32 (2010): 14134-14139.
[cited by applicant]
Graham, Laura, et al. “A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.” Investigational new drugs 36.3 (2018). 18 pages.
[cited by applicant]
Hsieh, Andrew C., Eric J. Small, and Charles J. Ryan. “Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development.” The lancet oncology 8.10 (2007): 933-939.
[cited by applicant]
Hisieh, Andrew C., et al. “Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.” Science signaling 8.403 (2015). 20 pages.
[cited by applicant]
Hsieh, Andrew C., et al. “Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-elF4E.” Cancer cell 17.3 (2010): 249-261.
[cited by applicant]
Hsieh, Andrew C., and Davide Ruggero. “Targeting eukaryotic translation initiation factor 4E (elF4E) in cancer.” Clinical cancer research 16.20 (2010): 4914-4920.
[cited by applicant]
Hsieh, Andrew C., et al. “The translational landscape of mTOR signalling steers cancer initiation and metastasis.” Nature 485.7396 (2012). 24 pages.
[cited by applicant]
Lawrence Jr, John C., and Robert T. Abraham. “PHAS/4E-BPs as regulators of mRNA translation and cell proliferation.” Trends in biochemical sciences 22.9 (1997): 345-349.
[cited by applicant]
Le Bacquer, Olivier, et al. “Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2.” The Journal of clinical investigation 117.2 (2007): 387-396.
[cited by applicant]
Moerke, Nathan J., et al. “Small-molecule inhibition of the interaction between the translation initiation factors elF4E and elF4G.” Cell 128.2 (2007): 257-267.
[cited by applicant]
Thoreen, Carson C., et al. “A unifying model for mTORC1-mediated regulation of mRNA translation.” Nature 485.7396 (2012). 17 pages.
[cited by applicant]
Tran, Chris, et al. “Development of a second-generation antiandrogen for treatment of advanced prostate cancer.” Science 324.5928 (2009). 11 pages.
[cited by applicant]
Tsai, Shih-Yin, et al. “Increased 4E-BP1 expression protects against diet-induced obesity and insulin resistance in male mice.” Cell reports 16.7 (2016). 13 pages.
[cited by applicant]
Watson, Philip A., Vivek K. Arora, and Charles L. Sawyers. “Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.” Nature Reviews Cancer 15.12 (2015). 27 pages.
[cited by applicant]
Wei, Xiao X., et al. “A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer.” The oncologist 22.5 (2017): 503-e43.
[cited by applicant]
Wu, Chun-Te, et al. “Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor.” Proceedings of the National Academy of Sciences 104.31 (2007): 12679-12…
[cited by applicant]
Yanagiya, Akiko, et al. “Translational homeostasis via the mRNA cap-binding protein, elF4E.” Molecular cell 46.6 (2012): 847-858.
[cited by applicant]
Ramamurthy et al., “Simultaneous Targeting of Androgen Receptor (AR) and MAPK-interacting Kinases (MNKS) by Novel Retinamides Inhibits Growth of Human Prostate Cancer Cell Lines,” Oncotarget, (6)5: 3195-3210, Dec. 2014.
[cited by applicant]
International Search Report and Written Opinion mailed Oct. 28, 2020, issued in corresponding International Application No. PCT/US2020/43203, filed Jul. 23, 2020, 8 pages.
[cited by applicant]